ECSP19035077A - Inhibidores de magl - Google Patents

Inhibidores de magl

Info

Publication number
ECSP19035077A
ECSP19035077A ECSENADI201935077A ECDI201935077A ECSP19035077A EC SP19035077 A ECSP19035077 A EC SP19035077A EC SENADI201935077 A ECSENADI201935077 A EC SENADI201935077A EC DI201935077 A ECDI201935077 A EC DI201935077A EC SP19035077 A ECSP19035077 A EC SP19035077A
Authority
EC
Ecuador
Prior art keywords
magl inhibitors
compositions
magl
useful
compounds
Prior art date
Application number
ECSENADI201935077A
Other languages
English (en)
Inventor
Michael B Shaghafi
Cheryl A Grice
Daniel J Buzard
Original Assignee
Abide Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abide Therapeutics Inc filed Critical Abide Therapeutics Inc
Publication of ECSP19035077A publication Critical patent/ECSP19035077A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/195—Radicals derived from nitrogen analogues of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan en este documento carbamatos de piperazina y composiciones farmacéuticas que comprenden dichos compuestos. Los compuestos y composiciones objeto son útiles como moduladores de MAGL. Adicionalmente, los compuestos y composiciones objeto son útiles para el tratamiento del dolor.
ECSENADI201935077A 2016-11-16 2019-05-16 Inhibidores de magl ECSP19035077A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662423099P 2016-11-16 2016-11-16

Publications (1)

Publication Number Publication Date
ECSP19035077A true ECSP19035077A (es) 2019-05-31

Family

ID=62106678

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201935077A ECSP19035077A (es) 2016-11-16 2019-05-16 Inhibidores de magl

Country Status (29)

Country Link
US (1) US10093635B2 (es)
EP (1) EP3541821A4 (es)
JP (1) JP7042547B2 (es)
KR (1) KR20190077544A (es)
CN (1) CN110267963B (es)
AR (1) AR110089A1 (es)
AU (1) AU2017361251B2 (es)
BR (1) BR112019009994A2 (es)
CA (1) CA3043615A1 (es)
CL (1) CL2019001339A1 (es)
CO (1) CO2019005059A2 (es)
CR (1) CR20190241A (es)
DO (1) DOP2019000122A (es)
EA (1) EA038090B1 (es)
EC (1) ECSP19035077A (es)
GE (2) GEAP202215088A (es)
IL (1) IL266523B (es)
JO (1) JOP20190106A1 (es)
MA (1) MA46857A (es)
MX (1) MX391117B (es)
NI (1) NI201900051A (es)
PE (1) PE20191144A1 (es)
PH (1) PH12019501097A1 (es)
RU (1) RU2754536C1 (es)
TN (1) TN2019000153A1 (es)
TW (1) TWI756299B (es)
UA (1) UA124542C2 (es)
WO (1) WO2018093947A1 (es)
ZA (1) ZA201903100B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2793148T3 (es) 2012-01-06 2020-11-13 Lundbeck La Jolla Research Center Inc Compuestos de carbamato y métodos para fabricarlos y usarlos
CA2984480A1 (en) 2015-05-11 2016-11-17 Abide Therapeutics, Inc. Methods of treating inflammation or neuropathic pain
US10899737B2 (en) 2016-09-19 2021-01-26 Lundbeck La Jolla Research Center, Inc. Piperazine carbamates and methods of making and using same
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
AU2017361254B2 (en) 2016-11-16 2021-09-23 H. Lundbeck A/S. Pharmaceutical formulations
EP3541807B1 (en) 2016-11-16 2021-09-29 H. Lundbeck A/S A crystalline form of a magl inhibitor
US10266497B2 (en) 2017-05-23 2019-04-23 Abide Therapeutics, Inc. Pyrazole MAGL inhibitors
CA3072923A1 (en) 2017-08-29 2019-03-07 Lundbeck La Jolla Research Center, Inc. Spirocycle compounds and methods of making and using same
CR20200545A (es) 2018-05-15 2020-12-17 Lundbeck La Jolla Research Center Inc Inhibidores magl
EP3914589A4 (en) * 2019-01-25 2022-11-30 H. Lundbeck A/S Methods of treating disease with magl inhibitors
AU2020383502A1 (en) * 2019-11-15 2022-06-30 H. Lundbeck A/S Crystalline forms of a MAGL inhibitor
IT202000007150A1 (it) * 2020-04-03 2021-10-03 Univ Pisa Inibitori di monoacilglicerolo lipasi (magl)
CN115427403A (zh) 2020-04-21 2022-12-02 H.隆德贝克有限公司 单酰基甘油脂肪酶抑制剂的合成
CA3242372A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
AU2023264787A1 (en) 2022-05-04 2024-10-31 H. Lundbeck A/S Crystalline form of 1,1,1,3,3,3-hexafluoropropan-2-yl (s)-1-(pyridazin-3-ylcarbamoyl)-6 azaspiro[2.5]octane-6-carboxylate as monoacylglycerol lipase inhibitor.

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1593586A (es) 1967-10-17 1970-06-01
JPS6183073A (ja) 1984-10-01 1986-04-26 Oki Electric Ind Co Ltd 印字装置の用紙送り方法
WO1989011794A1 (fr) 1988-06-07 1989-12-14 Rikagaku Kenkyusho Inhibiteur de la croissance de plantes
DE69211015T2 (de) 1991-11-27 1997-01-09 Du Pont Herbizide acylierte amino-(phenyl-oder-pyridinyl-oder thienyl-)phenyl derivate
DE69408873T2 (de) 1993-12-22 1998-07-09 Shell Int Research Verfahren zur herstellung von carbamaten
EP0863879A1 (en) 1995-11-15 1998-09-16 Zeneca Limited Herbicidal substituted pyrazole compounds
AU3440597A (en) 1996-07-02 1998-01-21 Novartis Ag N-phenylimino heterocyclic derivatives and their use as herbicides
RU2167150C2 (ru) 1998-03-25 2001-05-20 Фокин Александр Васильевич Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью
ATE432993T1 (de) 1999-10-04 2009-06-15 Univ New Jersey Med Tar rna bindende peptide
EP1201298A1 (en) 2000-10-24 2002-05-02 Urea Casale S.A. Carbamate condensation unit
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
FR2864080B1 (fr) 2003-12-23 2006-02-03 Sanofi Synthelabo Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
WO2005063698A1 (en) 2003-12-31 2005-07-14 Council Of Scientific & Industrial Research Process for preparing carbamates
KR20070026382A (ko) 2004-02-18 2007-03-08 아스트라제네카 아베 아세틸린성 피페라진 화합물 및 대사성 글루타메이트수용체 길항제로서 이들의 용도
CA2589877A1 (en) 2004-12-23 2006-06-29 F. Hoffmann-La Roche Ag Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
RS56194B1 (sr) 2004-12-30 2017-11-30 Janssen Pharmaceutica Nv Derivativi fenilamida 4-(benzil)-piperazin-1-karboksilne kiseline i slična jedinjenja kao modulatori hidrolaze amida masnih kiselina (faah) za lečenje anksioznosti, bola i ostalih stanja
US20080255150A1 (en) * 2005-11-05 2008-10-16 Astrazeneca Ab Novel Compounds
JP2009523729A (ja) 2006-01-13 2009-06-25 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎の治療方法
MX2009006706A (es) 2006-12-22 2009-07-02 Astex Therapeutics Ltd Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
CN101711154A (zh) 2007-02-26 2010-05-19 科森生物科学公司 氨基甲酸酯化合物
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
EP2328897A1 (en) 2008-07-16 2011-06-08 Schering Corporation Bicyclic heterocycle derivatives and their use as gpcr modulators
EP2373315A4 (en) 2008-11-14 2012-06-27 Scripps Research Inst METHOD AND COMPOSITIONS RELATED TO TARGETING OF MONOACYLGLYCEROLLIPASE
CA2755806A1 (en) 2009-03-23 2010-09-30 Msd K.K. Novel aminopyridine derivatives having aurora a selective inhibitory action
CA2759547A1 (en) * 2009-04-22 2010-10-28 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
ES2433235T3 (es) 2009-11-03 2013-12-10 Bayer Intellectual Property Gmbh Fluorouretanos como aditivos en una formulación de fotopolímero
FR2960875B1 (fr) * 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
KR101893112B1 (ko) 2012-01-06 2018-08-30 아지오스 파마슈티컬스 아이엔씨. 치료학적으로 활성인 화합물 및 이의 이용 방법
ES2793148T3 (es) 2012-01-06 2020-11-13 Lundbeck La Jolla Research Center Inc Compuestos de carbamato y métodos para fabricarlos y usarlos
WO2013142307A1 (en) 2012-03-19 2013-09-26 Abide Therapeutics Carbamate compounds and of making and using same
JP2014005245A (ja) * 2012-06-26 2014-01-16 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体を含有する医薬組成物
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
JP6647592B2 (ja) * 2013-07-03 2020-02-14 ルンドベック ラ ホーヤ リサーチ センター，インク． ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用
WO2016014975A2 (en) 2014-07-25 2016-01-28 Northeastern University Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof
CA2979537C (en) 2015-03-18 2023-08-29 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
US10899737B2 (en) * 2016-09-19 2021-01-26 Lundbeck La Jolla Research Center, Inc. Piperazine carbamates and methods of making and using same
JOP20190105A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)

Also Published As

Publication number Publication date
TN2019000153A1 (en) 2020-10-05
EP3541821A1 (en) 2019-09-25
EA201991073A1 (ru) 2019-12-30
BR112019009994A2 (pt) 2019-08-27
CN110267963B (zh) 2022-04-01
CO2019005059A2 (es) 2019-05-31
NI201900051A (es) 2019-10-30
AR110089A1 (es) 2019-02-20
MX2019005776A (es) 2019-12-05
EP3541821A4 (en) 2020-04-22
EA038090B1 (ru) 2021-07-05
CN110267963A (zh) 2019-09-20
IL266523A (en) 2019-07-31
PH12019501097A1 (en) 2019-08-19
AU2017361251A1 (en) 2019-05-30
US20180134674A1 (en) 2018-05-17
US10093635B2 (en) 2018-10-09
RU2754536C1 (ru) 2021-09-03
ZA201903100B (en) 2020-11-25
IL266523B (en) 2022-09-01
JOP20190106A1 (ar) 2019-05-09
CA3043615A1 (en) 2018-05-24
JP7042547B2 (ja) 2022-03-28
DOP2019000122A (es) 2019-09-30
NZ753264A (en) 2020-12-18
JP2020504707A (ja) 2020-02-13
GEAP202215088A (en) 2022-08-25
CL2019001339A1 (es) 2019-10-04
GEP20237470B (en) 2023-02-10
PE20191144A1 (es) 2019-09-02
WO2018093947A1 (en) 2018-05-24
RU2019116512A (ru) 2020-12-17
AU2017361251B2 (en) 2021-08-19
TWI756299B (zh) 2022-03-01
TW201823216A (zh) 2018-07-01
UA124542C2 (uk) 2021-10-05
CR20190241A (es) 2019-09-02
KR20190077544A (ko) 2019-07-03
MA46857A (fr) 2019-09-25
MX391117B (es) 2025-03-21

Similar Documents

Publication Publication Date Title
NI201900051A (es) Inhibidores de magl
ECSP19035377A (es) Inhibidores de magl
MX2020012158A (es) Inhibidores de magl.
ECSP19083923A (es) Inhibidores pirazólicos de magl
NI201900049A (es) Inhibidores de la magl
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2019003397A1 (es) Inhibidores pirazólicos de magl.
CL2019002583A1 (es) Inhibidores duales de magl y faah.
CR20190028A (es) Compuestos heterocíclicos como inmunomoduladores